Api

Weekly tactical pick: Does this pharma major merit a look despite the regulatory noises?

The fundamentals of the company should be judged based on the specialty pipeline and a strong footing in the domestic market

Ami Organics | Strong growth runway for the CDMO business? | Stock of the Day

Ami Organics gets 87 percent of the revenue comes from pharma space wherein it manufactures intermediates for APIs and NCE (New Chemical Entities). Rest of the revenue comes from chemicals segment. While company’s foray into the lithium-ion batteries and the semiconductor industry value chain is a key watch, ramp-up in CDMO (Contract Development and Manufacturing Organization) contracts is expected to be the key earnings catalyst. In the recent quarterly result, there was a sharp pick up in the CDMO business. At the same time, guidance for next three years suggest that high growth phase to sustain.

Bajaj Healthcare rises after CDMO pact for 15 new Active Pharma Ingredients

The new APIs are in addition to a contract for 15 molecules for the client signed earlier this year. Bajaj Healthcare said the new CDMO pipeline comprises of off-Patent generic APIs as well as APIs that are still under patent.

Healthcare, pharma deal values fall 67% YoY in March quarter: GT Bharat

The quarter also reported four IPOs totaling $466 million, a doubling in volumes compared to the previous quarter

Decoded: Sebi's proposed rules to regulate algo trading by retail traders

SEBI is concerned that algo developers promise lofty returns to gullible traders, and bypass SEBI rules applicable to registered investment advisors (RIA) as mandated by SEBI. Misselling too is a huge problem.

Ami Organics: Should one look beyond the sharp pricing erosion?

The pharma company is well positioned to take advantage of emerging opportunities

Ami Organics: Fermion contract raises FY25 earnings visibility

Capex in Ankleshwar, pick-up in supplies for Fermion and a foray into the electro-lyte additive business are the other factors prompting the company to expect a bounce-back in growth in FY25.

Concord Biotech: This niche API play rides on China-plus theme

The company has a good repute in the fermentation-based API segment. A number of fermentation-based biologic drugs are expected to lose exclusivity in the next two years, and this opens a $60 billion opportunity.

62% increase in API attacks on Indian financial sector: CERT-In joint white paper

The majority of cyber attacks on APIs deployed in the Indian financial sector was due to security misconfiguration, the joint white paper by CERT-In, Mastercard, and CSIRT-Fin said

Google announces new sustainability APIs for Maps

Google says companies can use these APIs to provide up-to-date environmental information to customers.

Ami Organics: Opportunities in battery value chain not priced in

Pickup in collaboration between global pharma majors and Indian firms for pharma ingredients/molecules, development of new products among positives.